MCL Literature Feed

In a large real-world analysis, R-CHOP/R-DHAP trended toward better OS in transplant-eligible patients, while rituximab maintenance, not initial chemo, drove survival in transplant-ineligible patients.

This retrospective analysis evaluates transplant outcomes in relapsed/refractory MCL after ibrutinib failure, identifying risk factors to guide patient selection for this intensive consolidation therapy.

This first real-world analysis of ASCT for MCL in Argentina confirms its efficacy but identifies blastoid variant, age ≥55, and high comorbidities as independent predictors of poor survival.

In a resource-limited setting, 12% of chemosensitive MCL patients progress by 3 months while awaiting autologous transplant, highlighting the need for prioritization and defining acceptable wait times.

An expert panel opinion advocates for personalized MCL therapy, positioning BTKi as a frontline standard for transplant-ineligible patients and a potential alternative to consolidation transplant for others.

Adding ibrutinib to intensive frontline immunochemotherapy for newly diagnosed, fit MCL patients aims to deepen responses and improve outcomes, often as induction before transplant consolidation.

Undetectable MRD after induction chemotherapy identifies mantle cell lymphoma patients who may safely omit consolidative autologous stem cell transplant, enabling a personalized, de-escalation treatment strategy.

This Chinese real-world study confirms autologous transplant consolidation improves survival in young, fit, lower-risk MCL, with added benefit from post-transplant maintenance using novel agents.

In the phase 3 TRIANGLE trial for young, fit MCL, adding ibrutinib to induction immunochemotherapy improves failure-free survival, with noninvasive genotyping confirming its efficacy and treatment dynamics.

This review summarizes the shift towards frontline BTK inhibitor-based regimens, including chemotherapy-free options and combinations for high-risk MCL, potentially replacing autologous stem cell transplant consolidation.

The phase 3 TRIANGLE trial shows adding ibrutinib to frontline chemoimmunotherapy and autologous transplant improves failure-free survival, establishing a new standard of care for young, fit MCL patients.

This paper on rhinosinusitis in a general post-transplant population is not specific to mantle cell lymphoma and provides no new insights for the MCL field.

In the MCL0208 trial for young patients, IGHV mutation status and stereotyped receptors predicted outcomes after intensive chemoimmunotherapy and transplant, offering a new biomarker for frontline risk stratification.

Pretargeted anti-CD20 radioimmunotherapy safely intensifies BEAM conditioning before autologous transplant in high-risk B-cell lymphomas, including MCL, offering a feasible new consolidation strategy.

A pooled analysis of six phase 3 trials shows median overall survival for young, fit MCL patients improved from 4.9 years to not reached, driven by intensified frontline chemoimmunotherapy and transplant.

This long-term Italian study confirms poor outcomes for allo-HSCT in relapsed/refractory MCL (27% 3-year PFS), with no survival benefit if not in complete remission pre-transplant.

This review argues that new agents like BTKi are disrupting the frontline MCL standard of care, challenging ASCT's role and demanding personalized, risk-adapted treatment guidelines to resolve clinical uncertainty.

Retrospective data show B symptoms and CBV conditioning negatively impact survival post-ASCT in MCL, supporting BeEAM conditioning and risk-adapted strategies for consolidation.

Korean real-world data confirms consolidative auto-SCT is effective, while in the relapsed setting, auto-SCT benefits chemosensitive patients and matched-donor allo-SCT is a viable option for refractory disease.

A four-decade analysis demonstrates significant, gradual overall survival improvement in MCL, validating the cumulative clinical impact of evolving therapies from chemotherapy to novel agents and transplant.

This meta-analysis in TP53-mutated MCL supports targeted therapy frontline and CAR-T or transplant in relapse, but confirms poor long-term survival, highlighting the need for novel approaches.

This case report describes therapy-related acute megakaryoblastic leukemia after autologous transplant for MCL, highlighting a rare but severe long-term toxicity of intensive consolidation therapy.

This review contrasts European and American perspectives on integrating autologous transplant, CAR-T, and allogeneic transplant into MCL treatment, offering clinical guidance in a rapidly evolving therapeutic landscape.

This case report details a rare presentation of MCL transformed to DLBCL with urinary symptoms from prostate involvement, highlighting lymphoma as a differential diagnosis requiring aggressive chemoimmunotherapy and transplant.

This review advocates for adding a BTKi to frontline immunochemotherapy for transplant-eligible patients as a new standard of care, while also summarizing its emerging role in older patients.

In a modern Canadian cohort, allogeneic transplant for relapsed/refractory MCL achieved a 5-year overall survival of 68.1%, confirming its ongoing relevance as a curative-intent therapy.

In older relapsed/refractory MCL patients, brexucabtagene autoleucel offers superior 1-year overall survival and lower non-relapse mortality versus allogeneic transplant, though long-term outcomes are similar, guiding treatment selection.

This real-world study from Colombia confirms the prognostic value of the MIPI score and the survival benefit of autologous stem cell transplant in a Latin American MCL cohort.

This large pooled analysis of 1280 trial patients validates progression within 24 months (POD24) as a robust indicator of poor survival, with rituximab maintenance reducing this risk.

In young, fit MCL patients undergoing frontline autotransplant, large clonal hematopoiesis clones (VAF ≥10%) at baseline are a novel biomarker for worse progression-free and overall survival.